Market Closed -
Euronext Bruxelles
11:35:14 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
18.24
EUR
|
-0.22%
|
|
+2.70%
|
+9.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,393
|
1,375
|
1,078
|
967.2
|
1,213
|
1,331
|
-
|
-
|
Enterprise Value (EV)
1 |
1,678
|
1,647
|
1,343
|
1,241
|
1,447
|
1,560
|
1,509
|
1,488
|
P/E ratio
|
34.5
x
|
22.9
x
|
17.6
x
|
13.8
x
|
17.1
x
|
16.2
x
|
13.9
x
|
12.2
x
|
Yield
|
0.78%
|
0.95%
|
1.35%
|
1.88%
|
1.81%
|
1.6%
|
1.74%
|
1.91%
|
Capitalization / Revenue
|
2.61
x
|
2.47
x
|
1.88
x
|
1.41
x
|
1.59
x
|
1.58
x
|
1.49
x
|
1.39
x
|
EV / Revenue
|
3.14
x
|
2.96
x
|
2.34
x
|
1.82
x
|
1.9
x
|
1.85
x
|
1.68
x
|
1.56
x
|
EV / EBITDA
|
14.3
x
|
13.3
x
|
11.4
x
|
9.5
x
|
9.71
x
|
9.33
x
|
8.29
x
|
7.53
x
|
EV / FCF
|
30.5
x
|
22.1
x
|
23.3
x
|
13.6
x
|
16.8
x
|
16.2
x
|
12.4
x
|
11.5
x
|
FCF Yield
|
3.28%
|
4.53%
|
4.29%
|
7.33%
|
5.96%
|
6.16%
|
8.04%
|
8.7%
|
Price to Book
|
5.73
x
|
5.41
x
|
3.36
x
|
2.39
x
|
2.61
x
|
2.52
x
|
2.18
x
|
1.9
x
|
Nbr of stocks (in thousands)
|
72,075
|
72,374
|
72,857
|
72,889
|
73,030
|
72,987
|
-
|
-
|
Reference price
2 |
19.33
|
19.00
|
14.80
|
13.27
|
16.61
|
18.24
|
18.24
|
18.24
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/9/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
534.7
|
556
|
573.8
|
683.9
|
763
|
841.2
|
895.4
|
955.1
|
EBITDA
1 |
117
|
123.9
|
118.3
|
130.7
|
149
|
167.2
|
182
|
197.6
|
EBIT
1 |
87.68
|
92.63
|
87.44
|
97.91
|
108.6
|
125.9
|
139.5
|
152.8
|
Operating Margin
|
16.4%
|
16.66%
|
15.24%
|
14.32%
|
14.24%
|
14.97%
|
15.58%
|
16%
|
Earnings before Tax (EBT)
1 |
69.89
|
73.72
|
-
|
-
|
-
|
107.4
|
123.4
|
136.6
|
Net income
1 |
41.06
|
60.04
|
61
|
69.61
|
70.55
|
82.27
|
96.23
|
109.9
|
Net margin
|
7.68%
|
10.8%
|
10.63%
|
10.18%
|
9.25%
|
9.78%
|
10.75%
|
11.51%
|
EPS
2 |
0.5600
|
0.8300
|
0.8400
|
0.9600
|
0.9700
|
1.123
|
1.310
|
1.493
|
Free Cash Flow
1 |
55
|
74.53
|
57.69
|
91
|
86.16
|
96
|
121.3
|
129.5
|
FCF margin
|
10.29%
|
13.41%
|
10.05%
|
13.31%
|
11.29%
|
11.41%
|
13.55%
|
13.56%
|
FCF Conversion (EBITDA)
|
47.01%
|
60.14%
|
48.75%
|
69.61%
|
57.84%
|
57.41%
|
66.65%
|
65.55%
|
FCF Conversion (Net income)
|
133.97%
|
124.14%
|
94.56%
|
130.72%
|
122.13%
|
116.69%
|
126.05%
|
117.83%
|
Dividend per Share
2 |
0.1500
|
0.1800
|
0.2000
|
0.2500
|
0.3000
|
0.2920
|
0.3180
|
0.3480
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/9/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2023 Q1
|
---|
Net sales
1 |
276.6
|
181.4
|
EBITDA
|
56.01
|
-
|
EBIT
|
40.72
|
-
|
Operating Margin
|
14.72%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
26.95
|
-
|
Net margin
|
9.74%
|
-
|
EPS
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
8/5/21
|
5/15/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
285
|
272
|
265
|
274
|
234
|
228
|
177
|
157
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.435
x
|
2.192
x
|
2.239
x
|
2.097
x
|
1.569
x
|
1.366
x
|
0.9742
x
|
0.7958
x
|
Free Cash Flow
1 |
55
|
74.5
|
57.7
|
91
|
86.2
|
96
|
121
|
130
|
ROE (net income / shareholders' equity)
|
25.9%
|
25.4%
|
21.3%
|
19.2%
|
16.2%
|
16.8%
|
16.7%
|
16.5%
|
ROA (Net income/ Total Assets)
|
7.83%
|
8.1%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
524.5
|
741.5
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.370
|
3.510
|
4.410
|
5.550
|
6.350
|
7.240
|
8.360
|
9.610
|
Cash Flow per Share
2 |
1.070
|
1.290
|
1.080
|
1.500
|
1.710
|
1.240
|
1.560
|
1.690
|
Capex
1 |
22.2
|
18.4
|
20.7
|
18.5
|
38.5
|
40.5
|
32.3
|
34.4
|
Capex / Sales
|
4.15%
|
3.31%
|
3.61%
|
2.71%
|
5.04%
|
4.81%
|
3.6%
|
3.6%
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/9/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
18.24
EUR Average target price
21.7
EUR Spread / Average Target +18.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.81% | 1.43B | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | -3.40% | 157B |
Other Pharmaceuticals
|